Jaka jest cena za Bellicum Pharmaceuticals, Inc. (BLCM)

Cena za Bellicum Pharmaceuticals, Inc. (BLCM) wynosi $0.07475

Jaka jest kapitalizacja rynkowa dla Bellicum Pharmaceuticals, Inc. (BLCM)

Kapitalizacja rynkowa dla Bellicum Pharmaceuticals, Inc. (BLCM) wynosi $755.60K

Bellicum Pharmaceuticals, Inc. (BLCM) Podziały Akcji

Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.

Rok	Podział	Mnożnik	Skumulowany mnożnik
Za mało danych dla podanych dat.

Rok

Podział

Mnożnik

Skumulowany mnożnik

Za mało danych dla podanych dat.

Firma	Liczba podziałów akcji	Skumulowany mnożnik	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Firma

Liczba podziałów akcji

Skumulowany mnożnik

Kraj